ML100 / Stanford University, University of Utah - LARVOL DELTA

Can Sacubitril-valsartan Improve Locomotor Muscle Microvascular Function In Heart Failure With Reduced Ejection Fraction? (ACSM 2024) - "Sacubitril-valsartan does not appear to improve locomotor muscle microvascular function in patients with HFrEF. These initial findings suggest that the beneficial effect of this drug on upper limb conduit artery function reported previously may not extend to the microcirculation of an ambulatory muscle group, highlighting a heterogeneous efficacy across different regions of the peripheral vasculature."

Cardiovascular • Congestive Heart Failure • Heart Failure

Reproducibility of arterial spin labeling cerebral blood flow image processing: A report of the ISMRM open science initiative for perfusion imaging (OSIPI)_and the ASL MRI challenge. (PubMed, Magn Reson Med) - "Variability in CBF measurements, influenced by differences in image processing, especially to compensate for motion, highlights the significance of standardizing ASL analysis workflows. We provide a recommendation for ASL processing based on top-performing approaches as a step toward ASL standardization."

Journal

Early-Frame [F]Florbetaben PET/MRI for Cerebral Blood Flow Quantification in Patients with Cognitive Impairment: Comparison to an [O]Water Gold Standard. (PubMed, J Nucl Med) - "Although previous methods could map relative CBF, quantitative measurement in absolute units (mL/100 g/min) remained challenging and has not been evaluated against the gold standard method of [O]water PET...There were no significant differences in performance between the methods in the amyloid-positive and amyloid-negative groups as well as participants with different cognitive statuses. We conclude that eFBB PET/MRI can provide robust CBF measurements, highlighting the capability of simultaneous PET/MRI to provide measurements of both CBF and amyloid burden in a single imaging session in participants with memory disorders."

Gold standard • Journal • Alzheimer's Disease • CNS Disorders • Cognitive Disorders • Dementia

Validation of early-frame 18F-FDG PET for CBF quantification: Comparison to simultaneous eASL measurements in memory patients (AAIC 2023) - "By simultaneous measurement of hemodynamics across modalities with a TOF-enabled PET/MRI, we were able to demonstrate that eFDG PET is a reliable measure in mapping CBF based on strong inter-modality correlation with ASL-CBF, irrespective of pathophysiological variations in memory patients."

Clinical • FDG PET • Alzheimer's Disease

Validation of early-frame 18F-FDG PET for CBF quantification: Comparison to simultaneous eASL measurements in memory patients (AAIC 2023) - "By simultaneous measurement of hemodynamics across modalities with a TOF-enabled PET/MRI, we were able to demonstrate that eFDG PET is a reliable measure in mapping CBF based on strong inter-modality correlation with ASL-CBF, irrespective of pathophysiological variations in memory patients."

Clinical • FDG PET • Alzheimer's Disease

Validation of early-frame 18F-FDG PET for CBF quantification: Comparison to simultaneous eASL measurements in memory patients (AAIC 2023) - "By simultaneous measurement of hemodynamics across modalities with a TOF-enabled PET/MRI, we were able to demonstrate that eFDG PET is a reliable measure in mapping CBF based on strong inter-modality correlation with ASL-CBF, irrespective of pathophysiological variations in memory patients."

Clinical • FDG PET • Alzheimer's Disease

Validation of early-frame 18F-FDG PET for CBF quantification: Comparison to simultaneous eASL measurements in memory patients (AAIC 2023) - "By simultaneous measurement of hemodynamics across modalities with a TOF-enabled PET/MRI, we were able to demonstrate that eFDG PET is a reliable measure in mapping CBF based on strong inter-modality correlation with ASL-CBF, irrespective of pathophysiological variations in memory patients."

Clinical • FDG PET • Alzheimer's Disease

Association of Intensive vs Standard Blood Pressure Control With Cerebral Blood Flow: Secondary Analysis of the SPRINT MIND Randomized Clinical Trial. (PubMed, JAMA Neurol) - P=N/A | "Mean whole-brain CBF increased from 38.90 to 40.36 (difference, 1.46 [95% CI, 0.08-2.83]) mL/100 g/min in the intensive treatment group, with no mean increase in the standard treatment group (37.96 to 37.12; difference, -0.84 [95% CI, -2.30 to 0.61] mL/100 g/min; between-group difference, 2.30 [95% CI, 0.30-4.30; P = .02])...Intensive vs standard antihypertensive treatment was associated with increased, rather than decreased, cerebral perfusion, most notably in participants with a history of cardiovascular disease. ClinicalTrials.gov Identifier: NCT01206062."

Clinical • Journal • Alzheimer's Disease • Cardiovascular • Chronic Kidney Disease • CNS Disorders • Dementia • Diabetes • Hypertension • Hypotension • Metabolic Disorders • Nephrology • Renal Disease

Acetazolamide-Challenged Arterial Spin Labeling Detects Augmented Cerebrovascular Reserve After Surgery for Moyamoya. (PubMed, Stroke) - "Acetazolamide-challenged arterial spin labeling noninvasively quantifies augmentation of CVR following surgery for Moyamoya disease and syndrome."

Journal • Cardiovascular • Giant Cell Arteritis • Immunology • Pediatrics • Vascular Neurology

Baseline Characteristics of Patients With Cavernous Angiomas With Symptomatic Hemorrhage in Multisite Trial Readiness Project. (PubMed, Stroke) - "These baseline features will aid investigators in patient stratification and determining the most appropriate outcome measures for clinical trials of emerging pharmacotherapies in CASH."

Clinical • Journal • Cardiovascular • Cerebral Hemorrhage • CNS Disorders • Depression • Hematological Disorders • Immunology • Mood Disorders • Psychiatry • MRI

Kidney Disease, Hypertension Treatment, and Cerebral Perfusion and Structure. (PubMed, Am J Kidney Dis) - "Among hypertensive adults with primarily early kidney disease, intensive versus standard blood pressure treatment did not appear to have a detrimental effect on brain perfusion or structure. The findings support the safety of intensive blood pressure treatment targets on brain health in persons with early kidney disease."

Journal • Chronic Kidney Disease • Hypertension • Nephrology • Renal Disease • MRI